Buy Protagonist (PTGX) After Icotyde Win — Commercial Upside + Pipeline Optionality
Protagonist Therapeutics just cleared a major commercial hurdle with Icotyde (icotrokinra) approval and a $50M milestone payment; the stock still offers upside as the market reprices recurring-revenue potential and waits on rusfertide and other pipeline moves. This trade idea takes a long stance with a 180-trading-day horizon and a clear entry, sto…